https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
There were no differences as far clinical presentation including disease severity, lesions types (urticarial and bullous) or mucosal involvement between g-BP and i-BP cases. The median antibody anti-BP180 and anti-BP230 titres was also similar between the two groups with 29.1 UI/mL (IQR 12.9-65.3) and 11.8 UI/mL (IQR 1.7-26.3), respectively. Gliptins were withdrawn in ten out of 15 patients and remission was achieved with systemic corticosteroids (0.3-0.7 mg/Kg daily) alone or in association with doxycycline (100-200 mg dail
Like
Comment
Share
